un de rd ev el op me nt Natural fast-acting liver protection for metabolic syndrome prevention and cardiovascular health Clinically supported product This innovative food supplement is based on an extract from a specific type of prune traditionally used in Asian diets for its hepatoprotective properties. Ideally suited for individuals at risk of metabolic syndrome or cardiovascular disease showing: • High levels of liver enzymes (AST, ALT and GGT) • Raised fasting plasma glucose • Increased LDL/HDL cholesterol ratio A randomized, double-blind, placebo controlled trial, including 45 people, showed significant results vs placebo with phenolic compounds contained in Livaker : • Lower serum enzymes levels (ALT, AST, GGT): -16 IU/L; -4 IU/L; -6 IU/L respectively • Lower glycemia: -7.6 mg/dL • Lower LDL/HDL ratio: -0.5 Why Livaker IDEAL NUTRACEUTICAL FOR : • Prevention of common metabolic & inflammation-based diseases • Protection of the liver in patients undergoing drug treatments or having high hepatic enzymes levels • Detoxification of the liver in case of diet unbalance or alcohol abuse D E VELOP MENT O F U NI Q U E , I NNO VA TI VE , C LI N I C A LLY PRO V E N PRO DU C T S TARGET INDICATION • Developed for people at risk of metabolic syndrome and cardiovascular disease (1,2) MANUFACTURING & SUPPLY REGULATORY • Tablets under development • Food supplement (EU) • Manufactured in the EU (GMP compliant) CLINICAL STUDIES • Several publications on the efficacy of this fruit extract are available. • Randomized, double-blind, placebo-controlled study (N=45, study period: 6 months). No minor or major adverse events were reported. Changes of liver enzymes versus baseline at 3 months Changes of glycemia and cholesterol level versus baseline at 3 months (mg/dL) 0 -4 IU/L -6 IU/L -16 IU/L -20 ALT AST Glycemia difference versus baseline Difference versus baseline 5 5 0.5 0 0 -20 GGT Placebo -0.5 -0.5 -1 -7.6 mg/dL LDL/HDL cholesterol (IU/L) -1.5 -2 Glycemia LDL/HDL cholesterol ratio Livaker * statistically significant vs placebo (p<0.05) 1. 2. Grundy SM. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007; 27(1):4-7. Niemela O, Alatalo P. Biomarkers of alcohol consumption and related liver disease. Scand J Clin Lab Invest 2010; 70(5):305-312. The trademark/brand name and claims herein are used by STRAGEN PHARMA SA for B2B purposes only. Any other use of this trademark/brand name requires STRAGEN’s prior written agreement. It is distributor’s responsibility to ensure compliance with applicable local regulations. STRAGEN PHARMA SA Chemin du Pré-Fleuri 3 Zone Industrielle 1228 Plan-les-Ouates / Geneva Switzerland Tel. +41 22 799 19 19 Fax +41 22 799 19 99 [email protected] www.stragenhealth.com D E VELOP MENT O F U NI Q U E , I NNO VA TI VE , C LI N I C A LLY PRO V E N PRO DU C T S October 2014 Significant (p<0.05) reduction of liver enzymes, glycemia and LDL/HDL ratio in less than 3 months.
© Copyright 2024 ExpyDoc
